Skip to main content
Erschienen in: Intensive Care Medicine 7/2010

01.07.2010 | Original

Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa

verfasst von: Qin Lu, Cassio Girardi, Mao Zhang, Belaïd Bouhemad, Kamel Louchahi, Olivier Petitjean, Frédéric Wallet, Marie-Helene Becquemin, Gilles Le Naour, Charles-Hugo Marquette, Jean-Jacques Rouby

Erschienen in: Intensive Care Medicine | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Emergence of multidrug-resistant strains in intensive care units has renewed interest in colistin, which often remains the only available antimicrobial agent active against resistant Pseudomonas aeruginosa. The aim of this study is to compare lung tissue deposition and antibacterial efficiency between nebulized and intravenous administration of colistin in piglets with pneumonia caused by P. aeruginosa.

Methods

In ventilated piglets, colistimethate was administered 24 h following bronchial inoculation of Pseudomonas aeruginosa (minimum inhibitory concentration of colistin = 2 μg ml−1) either by nebulization (8 mg kg−1 every 12 h, n = 6) or by intravenous infusion (3.2 mg kg−1 every 8 h, n = 6). All piglets were killed 49 h after inoculation. Colistin peak lung tissue concentrations and lung bacterial burden were assessed on multiple post mortem subpleural lung specimens.

Results

Median colistin peak lung concentration following nebulization was 2.8 μg g−1 (25–75% interquartile range = 0.8–13.7 μg g−1). Colistin was undetected in lung tissue following intravenous infusion. In the aerosol group, peak lung tissue concentrations were significantly greater in lung segments with mild pneumonia (median = 10.0 μg g−1, 25–75% interquartile range = 1.8–16.1 μg g−1) than in lung segments with severe pneumonia (median = 1.2 μg g−1, 25–75% interquartile range = 0.5–3.3 μg g−1) (p < 0.01). After 24 h of treatment, 67% of pulmonary segments had bacterial counts <102 cfu g−1 following nebulization and 28% following intravenous administration (p < 0.001). In control animals, 12% of lung segments had bacterial counts <102 cfu g−1 49 h following bronchial inoculation.

Conclusion

Nebulized colistin provides rapid and efficient bacterial killing in ventilated piglets with inoculation pneumonia caused by Pseudomonas aeruginosa.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Rouby JJ (1996) Nosocomial infection in the critically ill: the lung as a target organ. Anesthesiology 84:757–759CrossRefPubMed Rouby JJ (1996) Nosocomial infection in the critically ill: the lung as a target organ. Anesthesiology 84:757–759CrossRefPubMed
2.
Zurück zum Zitat Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274:639–644CrossRefPubMed Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274:639–644CrossRefPubMed
3.
Zurück zum Zitat Rello J, Mariscal D, March F, Jubert P, Sanchez F, Valles J, Coll P (1998) Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? Am J Respir Crit Care Med 157:912–916PubMed Rello J, Mariscal D, March F, Jubert P, Sanchez F, Valles J, Coll P (1998) Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? Am J Respir Crit Care Med 157:912–916PubMed
4.
Zurück zum Zitat Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr (1996) Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 109:1019–1029CrossRefPubMed Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr (1996) Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 109:1019–1029CrossRefPubMed
5.
Zurück zum Zitat Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A et al (2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13:560–578CrossRefPubMed Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A et al (2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13:560–578CrossRefPubMed
6.
Zurück zum Zitat Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL (2006) Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589–601CrossRefPubMed Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL (2006) Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589–601CrossRefPubMed
7.
Zurück zum Zitat Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40:1333–1341CrossRefPubMed Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40:1333–1341CrossRefPubMed
8.
Zurück zum Zitat Evans ME, Feola DJ, Rapp RP (1999) Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 33:960–967CrossRefPubMed Evans ME, Feola DJ, Rapp RP (1999) Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 33:960–967CrossRefPubMed
9.
Zurück zum Zitat Wolinsky E, Hines JD (1962) Neurotoxic and nephrotoxic effects of clolistin in patients with renal disease. N Engl J Med 266:759–762PubMedCrossRef Wolinsky E, Hines JD (1962) Neurotoxic and nephrotoxic effects of clolistin in patients with renal disease. N Engl J Med 266:759–762PubMedCrossRef
10.
Zurück zum Zitat Elwood CM, Lucas GD, Muehrcke RC (1966) Acute renal failure associated with sodium colistimethate treatment. Arch Intern Med 118:326–334CrossRefPubMed Elwood CM, Lucas GD, Muehrcke RC (1966) Acute renal failure associated with sodium colistimethate treatment. Arch Intern Med 118:326–334CrossRefPubMed
11.
Zurück zum Zitat Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, Hamida CB, Chaari A, Rekik N, Bouaziz M (2007) Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case–control study. Intensive Care Med 33:1162–1167CrossRefPubMed Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, Hamida CB, Chaari A, Rekik N, Bouaziz M (2007) Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case–control study. Intensive Care Med 33:1162–1167CrossRefPubMed
12.
Zurück zum Zitat Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittel IM, Gallego-Lara SL, Madrazo-Osuna J (2003) Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36:1111–1118CrossRefPubMed Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittel IM, Gallego-Lara SL, Madrazo-Osuna J (2003) Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36:1111–1118CrossRefPubMed
13.
Zurück zum Zitat Fica CA, Cespedes JI, Gompertz GM, Jalon VM, Sakurada ZA, Saez LE (2007) Intravenous colistin in the treatment of infections due to pan-resistant Gram negative bacilli. Rev Chilena Infectol 24:360–367 Fica CA, Cespedes JI, Gompertz GM, Jalon VM, Sakurada ZA, Saez LE (2007) Intravenous colistin in the treatment of infections due to pan-resistant Gram negative bacilli. Rev Chilena Infectol 24:360–367
14.
Zurück zum Zitat Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A (2006) Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 12:1227–1230CrossRefPubMed Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A (2006) Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 12:1227–1230CrossRefPubMed
15.
Zurück zum Zitat Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, Nation RL, Li J (2008) In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 62:1311–1318CrossRefPubMed Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, Nation RL, Li J (2008) In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 62:1311–1318CrossRefPubMed
16.
Zurück zum Zitat Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A et al (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53:3430–3436CrossRefPubMed Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A et al (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53:3430–3436CrossRefPubMed
17.
Zurück zum Zitat Rouby JJ, Goldstein I, Lu Q (2006) Inhaled antibiotic therapy. In: Tobin MJ (ed) Principles and practice of mechanical ventilation, Chapter 64, 2nd edn. McGraw-Hill, New York, pp 1311–1332 Rouby JJ, Goldstein I, Lu Q (2006) Inhaled antibiotic therapy. In: Tobin MJ (ed) Principles and practice of mechanical ventilation, Chapter 64, 2nd edn. McGraw-Hill, New York, pp 1311–1332
18.
Zurück zum Zitat Tonnellier M, Ferrari F, Goldstein I, Sartorius A, Marquette CH, Rouby JJ (2005) Intravenous versus nebulized ceftazidime in ventilated piglets with and without experimental bronchopneumonia: comparative effects of helium and nitrogen. Anesthesiology 102:995–1000CrossRefPubMed Tonnellier M, Ferrari F, Goldstein I, Sartorius A, Marquette CH, Rouby JJ (2005) Intravenous versus nebulized ceftazidime in ventilated piglets with and without experimental bronchopneumonia: comparative effects of helium and nitrogen. Anesthesiology 102:995–1000CrossRefPubMed
19.
Zurück zum Zitat Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette CH, Rouby JJ (2002) Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med 166:1375–1381CrossRefPubMed Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette CH, Rouby JJ (2002) Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med 166:1375–1381CrossRefPubMed
20.
Zurück zum Zitat Ferrari F, Lu Q, Girardi C, Petitjean O, Marquette CH, Wallet F, Rouby JJ (2009) Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa. Intensive Care Med 35:1792–1800CrossRefPubMed Ferrari F, Lu Q, Girardi C, Petitjean O, Marquette CH, Wallet F, Rouby JJ (2009) Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa. Intensive Care Med 35:1792–1800CrossRefPubMed
21.
Zurück zum Zitat Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME (2005) Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 9:R53–R59CrossRefPubMed Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME (2005) Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 9:R53–R59CrossRefPubMed
22.
Zurück zum Zitat Kwa AL, Loh C, Low JG, Kurup A, Tam VH (2005) Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 41:754–757CrossRefPubMed Kwa AL, Loh C, Low JG, Kurup A, Tam VH (2005) Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 41:754–757CrossRefPubMed
23.
Zurück zum Zitat Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H (2006) Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 57:306–311CrossRefPubMed Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H (2006) Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 57:306–311CrossRefPubMed
24.
Zurück zum Zitat Goldstein I, Wallet F, Robert J, Becquemin MH, Marquette CH, Rouby JJ (2002) Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med 165:171–175PubMed Goldstein I, Wallet F, Robert J, Becquemin MH, Marquette CH, Rouby JJ (2002) Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med 165:171–175PubMed
25.
Zurück zum Zitat Ferrari F, Liu ZH, Lu Q, Becquemin MH, Louchahi K, Aymard G, Marquette CH, Rouby JJ (2008) Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizers. Intensive Care Med 34:1718–1723CrossRefPubMed Ferrari F, Liu ZH, Lu Q, Becquemin MH, Louchahi K, Aymard G, Marquette CH, Rouby JJ (2008) Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizers. Intensive Care Med 34:1718–1723CrossRefPubMed
26.
Zurück zum Zitat Le Brun PP, de Graaf AI, Vinks AA (2000) High-performance liquid chromatographic method for the determination of colistin in serum. Ther Drug Monit 22:589–593CrossRefPubMed Le Brun PP, de Graaf AI, Vinks AA (2000) High-performance liquid chromatographic method for the determination of colistin in serum. Ther Drug Monit 22:589–593CrossRefPubMed
27.
Zurück zum Zitat Marquette CH, Wermert D, Wallet F, Copin MC, Tonnel AB (1999) Characterization of an animal model of ventilator-acquired pneumonia. Chest 115:200–209CrossRefPubMed Marquette CH, Wermert D, Wallet F, Copin MC, Tonnel AB (1999) Characterization of an animal model of ventilator-acquired pneumonia. Chest 115:200–209CrossRefPubMed
28.
Zurück zum Zitat Sartorius A, Lu Q, Vieira S, Tonnellier M, Lenaour G, Goldstein I, Rouby JJ (2007) Mechanical ventilation and lung infection in the genesis of air-space enlargement. Crit Care 11:R14CrossRefPubMed Sartorius A, Lu Q, Vieira S, Tonnellier M, Lenaour G, Goldstein I, Rouby JJ (2007) Mechanical ventilation and lung infection in the genesis of air-space enlargement. Crit Care 11:R14CrossRefPubMed
29.
Zurück zum Zitat Reina R, Estenssoro E, Saenz G, Canales HS, Gonzalvo R, Vidal G, Martins G, Das Neves A, Santander O, Ramos C (2005) Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31:1058–1065CrossRefPubMed Reina R, Estenssoro E, Saenz G, Canales HS, Gonzalvo R, Vidal G, Martins G, Das Neves A, Santander O, Ramos C (2005) Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31:1058–1065CrossRefPubMed
30.
Zurück zum Zitat Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC (2003) Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 47:905–909CrossRefPubMed Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC (2003) Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 47:905–909CrossRefPubMed
31.
Zurück zum Zitat Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, Etherington C, Turnidge J (2003) Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 52:987–992CrossRefPubMed Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, Etherington C, Turnidge J (2003) Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 52:987–992CrossRefPubMed
32.
Zurück zum Zitat Aoki N, Tateda K, Kikuchi Y, Kimura S, Miyazaki C, Ishii Y, Tanabe Y, Gejyo F, Yamaguchi K (2009) Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 63:534–542CrossRefPubMed Aoki N, Tateda K, Kikuchi Y, Kimura S, Miyazaki C, Ishii Y, Tanabe Y, Gejyo F, Yamaguchi K (2009) Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 63:534–542CrossRefPubMed
33.
Zurück zum Zitat Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ (1991) Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother 35:1953–1959PubMed Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ (1991) Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother 35:1953–1959PubMed
34.
Zurück zum Zitat Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, Rafailidis P, Apostolakos H, Baltopoulos G (2008) Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 30:143–151CrossRefPubMed Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, Rafailidis P, Apostolakos H, Baltopoulos G (2008) Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 30:143–151CrossRefPubMed
35.
Zurück zum Zitat Ryan G, Mukhopadhyay S, Singh M (2000) Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev CD001021 Ryan G, Mukhopadhyay S, Singh M (2000) Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev CD001021
36.
Zurück zum Zitat MacGowan AP, Wise R (2001) Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 48(suppl 1):17–28PubMed MacGowan AP, Wise R (2001) Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 48(suppl 1):17–28PubMed
37.
Zurück zum Zitat Elman M, Goldstein I, Marquette CH, Wallet F, Lenaour G, Rouby JJ (2002) Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia. Anesthesiology 97:199–206CrossRefPubMed Elman M, Goldstein I, Marquette CH, Wallet F, Lenaour G, Rouby JJ (2002) Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia. Anesthesiology 97:199–206CrossRefPubMed
38.
Zurück zum Zitat Barrowcliffe MP, Jones JG (1987) Solute permeability of the alveolar capillary barrier. Thorax 42:1–10CrossRefPubMed Barrowcliffe MP, Jones JG (1987) Solute permeability of the alveolar capillary barrier. Thorax 42:1–10CrossRefPubMed
39.
Zurück zum Zitat Brody JS, Vaccaro CA, Hill NS, Rounds S (1984) Binding of charged ferritin to alveolar wall components and charge selectivity of macromolecular transport in permeability pulmonary edema in rats. Circ Res 55:155–167PubMed Brody JS, Vaccaro CA, Hill NS, Rounds S (1984) Binding of charged ferritin to alveolar wall components and charge selectivity of macromolecular transport in permeability pulmonary edema in rats. Circ Res 55:155–167PubMed
40.
Zurück zum Zitat Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A (2009) Inhaled colistin as monotherapy for multidrug-resistant gram (−) nosocomial pneumonia: a case series. Respir Med 103:707–713CrossRefPubMed Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A (2009) Inhaled colistin as monotherapy for multidrug-resistant gram (−) nosocomial pneumonia: a case series. Respir Med 103:707–713CrossRefPubMed
41.
Zurück zum Zitat Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME (2008) Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 102:407–412CrossRefPubMed Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, Falagas ME (2008) Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 102:407–412CrossRefPubMed
Metadaten
Titel
Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa
verfasst von
Qin Lu
Cassio Girardi
Mao Zhang
Belaïd Bouhemad
Kamel Louchahi
Olivier Petitjean
Frédéric Wallet
Marie-Helene Becquemin
Gilles Le Naour
Charles-Hugo Marquette
Jean-Jacques Rouby
Publikationsdatum
01.07.2010
Verlag
Springer-Verlag
Erschienen in
Intensive Care Medicine / Ausgabe 7/2010
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-010-1879-4

Weitere Artikel der Ausgabe 7/2010

Intensive Care Medicine 7/2010 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.